Oncomine and TCGA results demonstrated increased expression of ACTB in multiple cancers like head and neck cancer, leukemia, pancreatic cancer, LIHC, KIRC compared with normal tissues, and ACTB expression was lower in several cancers like lung and prostate cancers. This evidence concerns the gene ACTB and prostate carcinoma.